Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 83 clinical trials
Featured trial
Fragile X Syndrome Clinical Study

This study will evaluate the efficacy and safety of ZYN002, a clear cannabidiol (CBD) gel that can be applied to the skin (called transdermal application) twice a day for the treatment of

fragile x syndrome
  • 77 views
  • 22 Dec, 2020
  • 1 location
None
Cannabidiol and Autonomic Function at Rest

Cannabidiol (CBD) is one of 700 chemicals derived from the Cannabis sativa plant and is both legal and widespread for distribution in the state of Vermont. The central hypothesis of this

  • 0 views
  • 15 Sep, 2021
  • 1 location
None
Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy

This protocol describes a phase II trial investigating the efficacy of CBD in paclitaxel- and oxaliplatin-induced peripheral neuropathy. The trial uses multiple assessments such as validated PRO-questionnaires and multifrequency vibrometry.

  • 0 views
  • 19 Jul, 2021
  • 1 location
None
Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine

The purpose of this week-long study is to determine the impact of cannabidiol on cue-induced cravings among individuals with opioid use disorder who are stable on sublingual buprenorphine

  • 0 views
  • 03 Feb, 2021
None
Clinical Study of Cannabidiol in Children and Adolescents With Fragile X Syndrome

This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of Cannabidiol (CBD) administered as ZYN002 for the treatment of children and

  • 0 views
  • 01 Dec, 2021
  • 13 locations
None
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

augmented with Cannabidiol Oral Solution (CBD) or with a matching CBD placebo for 8 weeks. The study will examine CBD as an augmentation strategy in early psychosis. It is hypothesized that CBD will improve

  • 0 views
  • 22 Jun, 2021
  • 2 locations
None
Investigation of the Pharmacokinetic Profile of CBD

pharmacokinetic (PK) effects of cannabidiol.

Accepts healthy volunteers
  • 0 views
  • 28 Nov, 2021
  • 1 location
None
Safety Pharmacokinetics and Exploratory Efficacy Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) Compared With Standard of Care Antiepileptic Therapy in Patients Age 1 Month to <12 Months of Age With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures

This study will be conducted to evaluate the safety, tolerability, and pharmacokinetics of GWP42003-P compared with standard of care (SOC) antiepileptic drug (AED) assessed during the 17-week treatment period.

  • 0 views
  • 06 Aug, 2021
  • 3 locations
None
Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa

No studies of cannabidiol (CBD) have focused on Anorexia Nervosa (AN). Dose, side effects, tolerability, acceptability of pure CBD in AN must be established. The current study is an important

  • 0 views
  • 27 Oct, 2021
  • 1 location
None
CBD Immune Function and Neural Health

controlling chronic inflammation and enhancing NK cell number and activity have been explored, relatively few have been administered without significant barriers. Cannabidiol (CBD), a non-psychoactive hemp

  • 0 views
  • 16 May, 2021
  • 1 location